Health ❯ Diabetes ❯ Type 2 Diabetes

Medications

GLP-1 Receptor Agonists Ozempic Semaglutide Mounjaro Ozempic and Mounjaro Orforglipron Insulin Production Retatrutide Extensior Tirzepatida GLP-1 Drugs GLP-1 Agonists Sémaglutide Tirzepatide FDA Approval Weight Management GLP-1 Injections

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Regulatory decisions await further phase 3 data in 2026.

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

Resalis’ miR-22 Antisense Shows Durable Fat Loss in Animals as Phase 1 Trial Continues

GLP-1 Drugs Linked to Lower Overall Cancer Risk in JAMA Oncology Analysis